A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive Patients

Learn more about:
Related Clinical Trial
Changes in Weight, Body Composition and Cardiac Risk After Discontinuing Abacavir Treatment in HIV-infected Individuals Changes in Weight, Body Composition and Metabolic Parameters After Discontinuing Dolutegravir or Tenofovir Disproxil Effect of Berberine on Metabolic Syndrome, Efficacy and Safety in Combination With Antiretroviral Therapy in PLWH. Hemoglobin Level, Coagulopathy Profile and Electrolyte Balance Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir® in HIV-Negative Healthy Subjects Myocardial Function & FFA Metabolism in HIV Metabolic Syndrome Exercise and Pioglitazone for HIV-Metabolic Syndromes Observational Study of Changes in Fat Distribution and Blood Metabolites in HIV Infected Adults Yoga for the Management of HIV-Metabolic Syndromes Pravastatin for Hyperlipidaemia in HIV. A Study of Physical and Metabolic Abnormalities in HIV Infected and Uninfected Children and Youth Exercise for Patients With HIV Infections Lactate Metabolism Study in HIV Infected Persons Quality of Life, Sleep, and Biomarkers in People With HIV/AIDS The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering Drugs Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Patients With Insulin and Fat Abnormalities Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV Patients Safety Study of Antria Cell Preparation Process to Enhance Facial Fat Grafting With Adipose Derived Stem Cells Growth Hormone Dynamics and Cardiac Steatosis in HIV The Effect of Anti-HIV Treatment on Body Characteristics of HIV-Infected Children Immune Response to Pneumococcal Vaccination in Aging HIV Positive Adults Switching From Zidovudine to an NNRTI or Lopinavir/Ritonavir in Patients Treated With Zidovudine/ Lamivudine/Abacavir. Phase 1 Study to Assess the Safety and Tolerability of TAT4 Gel in Healthy Volunteers Detraining in People Living With HIV/AIDS SHARE: Simple HAART With Abacavir, Reyataz, and Epivir The Effects of Anabolic Steroids and Protease Inhibitors on People Living With HIV/AIDS Observational Study of Fat Loss in HIV Infected Adults Taking Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Metabolism and Body Shape of Healthy Children and Children With Chronic Infections Changing to Nonprotease Inhibitor Treatment to Improve Side Effects Safety and Effectiveness of Fenofibrate and Pravastatin in HIV-Positive Patients With Abnormal Blood Lipids Perceived Changes in Body Build and Image in Patients Who Are Now Taking or Recently Have Stopped Taking Anti-HIV Drugs White Light Scanning to Aid Body Contouring: A Pilot Project Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients The Effect of Low-Dose Human Growth Hormone Therapy in HIV Infected Patients Study Comparing Reducing the Dose of Stavudine Versus Switching to Tenofovir in HIV-Infected Patients Receiving Antiretroviral Therapy The Cleveland Cardiometabolic Cohort Metabolic Abnormalities in HIV-infected Persons Clinical Evaluation of Venus Versa Octipolar Applicator for Reduction of Abdomen Circumference Factors Mediating Gut Microbiota Dysbiosis and Metabolic Disease in HIV Patients. Underlying Abnormalities in Fat and Muscle Leading to Lipodystrophy Syndrome Effects of Short-term Growth Hormone in HIV-infected Patients Safety Study of Filler Agent Composed of Autologous Mesenchymal Stem Cells and Hyaluronic Acid Raltegravir Therapy for Women With HIV and Fat Accumulation The PREFORM Study: A Study to Evaluate the Safety and Efficacy of Rotational Fractional Resection on Submental Contouring Effects of IGF-I in HIV Metabolic Disease Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome Effectiveness of Nucleoside Supplementation or Switch to Tenofovir in Reversing Fat Loss in HIV Infected Adults Lopinavir/r Monotherapy Versus Abacavir/Lamivudine and Lopinavir/r for Limb Fat Recovery in Persons With Lipoatrophy Effects of Growth Hormone Releasing Hormone in HIV A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive Patients Effects of a Uridine Supplement on HIV Infected Adults With Lipoatrophy Body Composition and Adipose Tissue in HIV Study to Evaluate Changes in Limb Fat When Switching From a Thymidine Analogue CONFORM: Rotational Fractional Resection for Submental Contouring Study of Alpha-2 Adrenergic Receptor Dysfunction in Regional Lipoatrophy TH9507 in Patients With HIV-Associated Lipodystrophy TH9507 Extension Study in Patients With HIV- Associated Lipodystrophy Study Evaluating the Impact on Fat Distribution of Nucleoside Reverse Transcriptase Inhibitor (NRTI)-Sparing Regimens in Antiretroviral Experienced Patients With Lipoatrophy Energy Expenditure of People Living With HIV/AIDS Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS) Egrifta Replacement and Sleep Disordered Breathing Clinical Trial to Determine the Efficacy of Sculptra™ Dermal Filler for the Correction of Contour Deformities Caused by Lipoatrophy Clinical Trial to Assess the Effect of the Change of Efavirenz (EFV) for Lopinavir/Ritonavir (LPV/r) in Lipoatrophy in HIV-infected Patients Low Energy Diet and Familial Partial Lipodystrophy Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy A Study to Determine How and Why HIV-Infected Subjects on Anti-viral Treatment Develop Lipodystrophy Adipocyte, Insulin-resistance and Immunity : Evaluation of Interleukin-7 in Lipodystrophy, Diabetes and Obesity Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy Role of the Autonomic Nervous System in HIV-Lipodystrophy Leptin for Abnormal Lipid Kinetics in HIV Lipodystrophy Syndrome Therapeutic Approaches to HAART-Induced Lipodystrophy Different Surgical Modalities for Thigh Lipodystrophy Including Liposuction,Thigh Lift and Liposuction Assisted Thigh Lift Leptin to Treat Lipodystrophy Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy Prevalence of Lipodystrophy Syndrome and Its Role as Cause of Metabolic Disturbances Efficacy, Safety and Tolerability of ISIS 304801 in People With Partial Lipodystrophy With an Open-Label Extension Shock Waves for Treatment of Gynoid Lipodystrophy and Localized Fat Corticosteroid-induced Lipodystrophy and Adipokines Short-term Effects of Leptin in People With Lipodystrophy Leptin to Treat Lipodystrophy Lipodystrophy Connect Patient Registry An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy Autologous Adipose-Derived Stem Cell Transplantation in Patients With Lipodystrophy

Brief Title

A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive Patients

Official Title

Glaxo Wellcome Trial to Assess the Regression of Hyperlactatemia and to Evaluate the Regression of Established Lipodystrophy in HIV-1-Positive Subjects (TARHEEL)

Brief Summary

      The purpose of this study is to see if the findings of increased lactic acid and abnormal fat
      distribution get better when d4T is replaced with abacavir, abacavir plus lamivudine, or
      Combivir (a pill containing lamivudine plus zidovudine) in HIV-positive patients taking
      anti-HIV therapy including stavudine (d4T).
    

Detailed Description

      Patients are allocated as follows: a) zidovudine-naive patients switch Combivir for d4t and
      b) zidovudine-experienced or -intolerant patients switch abacavir for d4t. Providers may
      choose between Combivir or abacavir as a switch for d4t when screening lactate levels are 2.2
      mmol/L or more. Additionally, providers may choose to switch a maximum of 2 drugs, one of
      which must be d4t, in the regimen. Each patient receives 48 weeks of therapy. Visits are made
      at Weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, and 48. Tests, including biopsies, are performed to
      measure changes in body fat distribution and changes in lactate levels. Virologic and
      immunologic outcomes, changes in physical signs of lipodystrophy, changes in self-reports of
      health-related quality-of-life survey and the Body Image Questionnaire, changes in lipid
      profile and other markers of metabolism, and safety parameters are evaluated also.
    

Study Phase

Phase 4

Study Type

Interventional




Condition

HIV Infections

Intervention

Lamivudine/Zidovudine


Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

100

Start Date

May 2000



Eligibility Criteria

        Inclusion Criteria

        Patients may be eligible for this study if they:

          -  Are HIV-positive.

          -  Are at least 18 years old.

          -  Agree not to have intercourse 2 weeks before, during, and 2 weeks after study or agree
             to use effective methods of birth control.

          -  Have had HIV-1 RNA levels less than 400 copies/ml on the 2 most recent measurements.

          -  Have at least 1 of the following situations:

          -  (a) at least 1 of the following: (1) decrease in facial fat, (2) decrease in fat in
             lower limbs, or (3) decrease in fat in buttocks area; or

          -  (b) an increase in lactate level greater than 2.2 mmol/L at the screening visit plus
             at least 1 of the following: (1) decrease in facial fat, (2) decrease in fat in lower
             limbs, or (3) decrease in fat in the buttocks area; or

          -  (c) an increase in lactate level greater than 2.2 mmol/L at screening visit plus at
             least 2 of the following: (1) shortness of breath, (2) weakness, (3) fast heartbeat,
             (4) recent weight loss (10 lbs. within the past 2 months), (5) pain and/or bloating in
             the abdomen, (6) nausea and/or vomiting and/or lack of appetite; or

          -  (d) lactate level greater than 3.2 mmol/L at the screening visit.

          -  Are able to read at a sixth-grade level.

          -  Have taken d4T consistently for the 6 months before entering study.

        Exclusion Criteria

        Patients will not be eligible for this study if they:

          -  Have diabetes or kidney failure.

          -  Have any condition that makes them unable to participate in this study.

          -  Are unable to take medications by mouth.

          -  Have serious medical conditions, such as congestive heart failure or other heart
             disease, which would affect the safety of the patient.

          -  Are taking or have taken abacavir plus Retrovir or Combivir.

          -  Are pregnant or breast-feeding.

          -  Are enrolled in other clinical studies.

          -  Have had a reaction to or are unable to take abacavir and have taken Retrovir in the
             past.

          -  Have taken hydroxyurea within the past 3 days or plan to take this drug during the
             study.

          -  Have had chemotherapy or radiation therapy within 4 weeks prior to screening visit
             (except for local treatment for Kaposi's sarcoma) or plan to have such treatment
             during the study.

          -  Have taken drugs that affect the immune system, such as systemic corticosteroids,
             interleukins, vaccines, or interferons, within 4 weeks prior to the screening visit.

          -  Have had an HIV vaccine within 3 months of the screening visit.

          -  Have taken recombinant Human Growth Hormone (r-hGH), megestrol acetate, medicines
             containing oxandrolone, oxymetholone, nandrolone, DHEA, or other testosterone
             derivatives, or glucocorticoids or other systemic steroids (except inhaled and topical
             steroids) in the last 4 months or plan to take these drugs during the study.
      

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

, , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT00005764

Organization ID

238T

Secondary IDs

ESS40010


Study Sponsor

Glaxo Wellcome


Study Sponsor

, , 


Verification Date

June 2001